The Pharma Data

MAY 2, 2021

With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems. The study aims to confirm that the proposed biosimilar has equivalent efficacy and comparable safety to the reference medicine* in patients with nAMD 1. billion.

Clinical Development 40

Clinical Development Medicine Development Production 40

The Pharma Data

MARCH 22, 2023

The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira ® * (adalimumab), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis. Head of North America.

FDA Approval 40

FDA Approval Generic Pharmaceutical Medicine Protein 40

The Pharma Data

APRIL 4, 2023

The approval includes all indications covered by the reference medicine*: rheumatic diseases, Crohn’s disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa. It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development.

Medicine 40

Medicine Generic Pharmaceutical FDA Approval Marketing 40

Pharmaceutical Technology

DECEMBER 22, 2022

Financing recognises companies and institutions that have raised significant capital during the research period whether it be through corporate finance, the capital markets or fund raising. Blueprint Medicines wins the Financing award this year after securing significant financing partnerships worth up to $1.25bn.

Insulin 130

Insulin Production Development Genetics 130

Pharmaceutical Technology

FEBRUARY 18, 2023

Novartis Overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. The company offers generic medicines and biosimilars through Sandoz.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

The Pharma Data

JUNE 17, 2022

Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Medicines Agency (EMA) has accepted the application for high concentration formulation 100 mg/mL (HCF) of its biosimilar Hyrimoz ® (adalimumab) for regulatory review. Source link: [link].

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

XTalks

JUNE 8, 2022

In a press release , the company says the goal of the Act4Biosimilars campaign is to help “address global health inequity and inequality” by increasing access to advanced medicines like biosimilars. As a result, the company is currently embroiled in legal disputes over claims of creating a market monopoly. percent.

Generic Pharmaceutical 69

Generic Pharmaceutical Branding Production Medicine 69

The Pharma Data

MARCH 15, 2022

Agency Supports Development of Complex Generic Drug-Device Combination Product to Improve Competition and Access to More Affordable Medicines. director of the Office of Generic Drugs in the FDA Center for Drug Evaluation and Research. Today, the U.S.

FDA Approval 52

FDA Approval Generic Drugs Production Drugs 52

Pharma in Brief

SEPTEMBER 19, 2023

Background All three decisions arose during proceedings commenced pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (the Regulations ). In defence, the Defendants allege that the patents are invalid.

Regulation 52

Regulation Generic Pharmaceutical Compliance Medicine 52

Pharmaceutical Technology

MARCH 22, 2023

In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. Only 25% of API production for generic drugs took place in Europe in 2020, according to a November 2022 Medicines for Europe report.

Production 263

Production Manufacturing Generic Drugs Drugs 263

FDA Law Blog

JANUARY 24, 2024

If this vision is achieved, the United States can bring innovative biotechnologies and products to markets faster while building a more robust supply chain ecosystem. generic pharmaceutical industry, resulting in low profit-margins. The four panels of experts focused on: (1) Current U.S.

Manufacturing 69

Manufacturing Drugs Generic Pharmaceutical Production 69

The Pharma Data

MAY 15, 2023

Before joining EMMI Group as CEO, he was a Member of the Executive Board and Head of the Marketing Department at Migros-Genossenschafts-Bund. He holds a Master degree in Marketing and Trade from the University of St. About Novartis Novartis is reimagining medicine to improve and extend people’s lives. Gallen (HSG), Switzerland.

Sales 40

Sales Production Doctors Doctor 40

The Pharma Data

MAY 18, 2021

By modernizing and simplifying its manufacturing setup, Sandoz will improve its ability to consistently deliver high-quality medicines to patients, while remaining cost-competitive on the global market. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. billion.

Manufacturing 40

Manufacturing Production Containment Generic Pharmaceutical 40

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33

Sales 98

Sales Manufacturing FDA Approval Life Science 98